Shopping Cart 0
Cart Subtotal
USD 0

CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 525
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

CRISPR Therapeutics-Strategy, SWOT and Corporate Finance Report

Summary

CRISPR Therapeutics-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.

Key Highlights

CRISPR Therapeutics AG (CRISPR) is a gene editing company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. The company classifies its business into single operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing technology. Through its CRISPR/Cas9 gene-editing technology, the company allows selective deletion, modification or correction of a disease causing abnormality in a specific DNA segment. It primarily operates in Switzerland, the UK, and the US. The company is headquartered in Basel, Switzerland.

Scope

- Detailed information on CRISPR Therapeutics required for business and competitor intelligence needs

- A study of the major internal and external factors affecting CRISPR Therapeutics in the form of a SWOT analysis

- An in-depth view of the business model of CRISPR Therapeutics including a breakdown and examination of key business segments

- Intelligence on CRISPR Therapeutics's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about CRISPR Therapeutics, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of CRISPR Therapeutics and the factors that influence its strategies.

- Track strategic initiatives of the company and latest corporate news and actions.

- Assess CRISPR Therapeutics as a prospective partner, vendor or supplier.

- Support sales activities by understanding your customers' businesses better.

- Stay up to date on CRISPR Therapeutics's business structure, strategy and prospects.

READ MORE

Table Of Content

Scope

Table of Contents

Company Snapshot 2

Table of Contents 5

CRISPR Therapeutics: Company Overview 9

CRISPR Therapeutics: Overview and Key Facts 9

CRISPR Therapeutics: Overview 9

CRISPR Therapeutics: Key Facts 9

CRISPR Therapeutics: Key Employees 10

CRISPR Therapeutics: Key Employee Biographies 11

CRISPR Therapeutics: Major Products and Services 12

CRISPR Therapeutics: Company History 13

CRISPR Therapeutics: Management Statement 15

CRISPR Therapeutics: Locations and Subsidiaries 16

CRISPR Therapeutics: Key Competitors 17

CRISPR Therapeutics: Company Analysis 18

CRISPR Therapeutics: Business Description 18

CRISPR Therapeutics: SWOT Analysis 19

CRISPR Therapeutics: SWOT Overview 19

CRISPR Therapeutics: Strengths 19

CRISPR Therapeutics: Weaknesses 20

CRISPR Therapeutics: Opportunities 20

CRISPR Therapeutics: Threats 21

CRISPR Therapeutics: Corporate Financial Deals Activity 23

CRISPR Therapeutics: Financial Deals Overview 23

CRISPR Therapeutics: Targets and Partners 25

CRISPR Therapeutics: Top Deals 2014-2018YTD* 27

CRISPR Therapeutics: Advisors 28

CRISPR Therapeutics: Top Legal Advisors 28

CRISPR Therapeutics: Top Financial Advisors 28

CRISPR Therapeutics: Capital Raising 29

CRISPR Therapeutics: Partnership 30

CRISPR Therapeutics: Private Equity and Ownership 31

CRISPR Therapeutics: Recent Developments 32

CRISPR Therapeutics: News and Events Summary 32

CRISPR Therapeutics: Business Expansion 35

CRISPR Therapeutics: Corporate Governance 36

CRISPR Therapeutics: Financial Performance 36

CRISPR Therapeutics: Market Developments 36

CRISPR Therapeutics: Research & Development 39

CRISPR Therapeutics: Strategy and Operations 40

Appendix 41

Contact Us 41

Methodology 41

About MarketLine 42


List Of Figure

List of Figures

Figure 1: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (TTM*)

Figure 2: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (2014-YTD*2018)

Figure 3: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2014-YTD*2018)

Figure 4: CRISPR Therapeutics: Capital Raising by Deal Type (2014-YTD*2018)

Figure 5: CRISPR Therapeutics: Partnership Volume and Value Trend (2014-YTD*2018)

Figure 6: CRISPR Therapeutics: Partnership Trend by Deal Type (2014-YTD*2018)

Figure 7: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2014-YTD*2018)

Figure 8: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2014-YTD*2018)


List Of Table

List of Tables

Table 1: CRISPR Therapeutics: Key Facts

Table 2: CRISPR Therapeutics: Key Employees

Table 3: CRISPR Therapeutics: Locations and Subsidiaries

Table 4: CRISPR Therapeutics: Key Competitors

Table 5: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (TTM*)

Table 6: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (2014-YTD*2018)

Table 7: CRISPR Therapeutics: Targets and Partners

Table 8: CRISPR Therapeutics: Top Deals 2014-2018YTD*

Table 9: CRISPR Therapeutics: Legal Advisor Ranking by Value (USUSDm)

Table 10: CRISPR Therapeutics: Financial Advisor Ranking by Value (USUSDm)

Table 11: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2014-YTD*2018)

Table 12: CRISPR Therapeutics: Capital Raising by Deal Type (2014-YTD*2018)

Table 13: CRISPR Therapeutics: Partnership Volume and Value Trend (2014-YTD*2018)

Table 14: CRISPR Therapeutics: Partnership Trend by Deal Type (2014-YTD*2018)

Table 15: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2014-YTD*2018)

Table 16: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2014-YTD*2018)

Table 17: CRISPR Therapeutics: News and Events Summary

Table 18: CRISPR Therapeutics: Business Expansion

Table 19: CRISPR Therapeutics: Corporate Governance

Table 20: CRISPR Therapeutics: Financial Performance

Table 21: CRISPR Therapeutics: Market Developments

Table 22: CRISPR Therapeutics: Research & Development

Table 23: CRISPR Therapeutics: Strategy and Operations

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

CRISPR Therapeutics-Strategy, SWOT and Corporate Finance Report

Summary

CRISPR Therapeutics-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.

Key Highlights

CRISPR Therapeutics AG (CRISPR) is a gene editing company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. The company classifies its business into single operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing technology. Through its CRISPR/Cas9 gene-editing technology, the company allows selective deletion, modification or correction of a disease causing abnormality in a specific DNA segment. It primarily operates in Switzerland, the UK, and the US. The company is headquartered in Basel, Switzerland.

Scope

- Detailed information on CRISPR Therapeutics required for business and competitor intelligence needs

- A study of the major internal and external factors affecting CRISPR Therapeutics in the form of a SWOT analysis

- An in-depth view of the business model of CRISPR Therapeutics including a breakdown and examination of key business segments

- Intelligence on CRISPR Therapeutics's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about CRISPR Therapeutics, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of CRISPR Therapeutics and the factors that influence its strategies.

- Track strategic initiatives of the company and latest corporate news and actions.

- Assess CRISPR Therapeutics as a prospective partner, vendor or supplier.

- Support sales activities by understanding your customers' businesses better.

- Stay up to date on CRISPR Therapeutics's business structure, strategy and prospects.

READ MORE

Scope

Table of Contents

Company Snapshot 2

Table of Contents 5

CRISPR Therapeutics: Company Overview 9

CRISPR Therapeutics: Overview and Key Facts 9

CRISPR Therapeutics: Overview 9

CRISPR Therapeutics: Key Facts 9

CRISPR Therapeutics: Key Employees 10

CRISPR Therapeutics: Key Employee Biographies 11

CRISPR Therapeutics: Major Products and Services 12

CRISPR Therapeutics: Company History 13

CRISPR Therapeutics: Management Statement 15

CRISPR Therapeutics: Locations and Subsidiaries 16

CRISPR Therapeutics: Key Competitors 17

CRISPR Therapeutics: Company Analysis 18

CRISPR Therapeutics: Business Description 18

CRISPR Therapeutics: SWOT Analysis 19

CRISPR Therapeutics: SWOT Overview 19

CRISPR Therapeutics: Strengths 19

CRISPR Therapeutics: Weaknesses 20

CRISPR Therapeutics: Opportunities 20

CRISPR Therapeutics: Threats 21

CRISPR Therapeutics: Corporate Financial Deals Activity 23

CRISPR Therapeutics: Financial Deals Overview 23

CRISPR Therapeutics: Targets and Partners 25

CRISPR Therapeutics: Top Deals 2014-2018YTD* 27

CRISPR Therapeutics: Advisors 28

CRISPR Therapeutics: Top Legal Advisors 28

CRISPR Therapeutics: Top Financial Advisors 28

CRISPR Therapeutics: Capital Raising 29

CRISPR Therapeutics: Partnership 30

CRISPR Therapeutics: Private Equity and Ownership 31

CRISPR Therapeutics: Recent Developments 32

CRISPR Therapeutics: News and Events Summary 32

CRISPR Therapeutics: Business Expansion 35

CRISPR Therapeutics: Corporate Governance 36

CRISPR Therapeutics: Financial Performance 36

CRISPR Therapeutics: Market Developments 36

CRISPR Therapeutics: Research & Development 39

CRISPR Therapeutics: Strategy and Operations 40

Appendix 41

Contact Us 41

Methodology 41

About MarketLine 42


List Of Figure

List of Figures

Figure 1: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (TTM*)

Figure 2: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (2014-YTD*2018)

Figure 3: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2014-YTD*2018)

Figure 4: CRISPR Therapeutics: Capital Raising by Deal Type (2014-YTD*2018)

Figure 5: CRISPR Therapeutics: Partnership Volume and Value Trend (2014-YTD*2018)

Figure 6: CRISPR Therapeutics: Partnership Trend by Deal Type (2014-YTD*2018)

Figure 7: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2014-YTD*2018)

Figure 8: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2014-YTD*2018)


List Of Table

List of Tables

Table 1: CRISPR Therapeutics: Key Facts

Table 2: CRISPR Therapeutics: Key Employees

Table 3: CRISPR Therapeutics: Locations and Subsidiaries

Table 4: CRISPR Therapeutics: Key Competitors

Table 5: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (TTM*)

Table 6: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (2014-YTD*2018)

Table 7: CRISPR Therapeutics: Targets and Partners

Table 8: CRISPR Therapeutics: Top Deals 2014-2018YTD*

Table 9: CRISPR Therapeutics: Legal Advisor Ranking by Value (USUSDm)

Table 10: CRISPR Therapeutics: Financial Advisor Ranking by Value (USUSDm)

Table 11: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2014-YTD*2018)

Table 12: CRISPR Therapeutics: Capital Raising by Deal Type (2014-YTD*2018)

Table 13: CRISPR Therapeutics: Partnership Volume and Value Trend (2014-YTD*2018)

Table 14: CRISPR Therapeutics: Partnership Trend by Deal Type (2014-YTD*2018)

Table 15: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2014-YTD*2018)

Table 16: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2014-YTD*2018)

Table 17: CRISPR Therapeutics: News and Events Summary

Table 18: CRISPR Therapeutics: Business Expansion

Table 19: CRISPR Therapeutics: Corporate Governance

Table 20: CRISPR Therapeutics: Financial Performance

Table 21: CRISPR Therapeutics: Market Developments

Table 22: CRISPR Therapeutics: Research & Development

Table 23: CRISPR Therapeutics: Strategy and Operations

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com
chat_bubbleLet's Chat